Palivizumab was the only approved therapy to prevent severe RSV disease in infants and young children until the approval of nirsevimab in 2023.

CELZ-201-DDT is a regenerative stem cell-based therapy being developed as a potential treatment for chronic low back pain associated with degenerative disc disease.